This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs. FogPharma is preclinical, but not for long.
Health tech to support care for seniors and track the progression of conditions such as Parkinson’s disease and heart failure were on display at HLTH 2023. The National Institute on Aging also added a startup boot camp leading up to HLTH.
After leading Novartis and Roche through pivotal years in 2023, the CEOs of the Swiss drug giants each netted multimillion-dollar compensation packages. After leading Swiss drug giants Novartis and Roche through pivotal years, their CEOs have each netted multimillion-dollar compensation packages for 2023.
In a year that started with more than two-thirds of biopharma companies posting | While Novo Nordisk and Eli Lilly continued to be the biopharma industry growth leaders in the fourth quarter of 2023, many other drugmakers also delivered big gains, including Daiichi Sankyo, Amgen, Teva, GSK and Novartis.
Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk and Eli Lilly—overwhelming the market wi | Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk (..)
In the 12 months leading up to May 15, health services deal volumes decreased just 4% from the year prior, a new report from PwC found. There was a 15% decrease in deal values.
The Moderna Innovation and Technology Centre (MITC) began construction in April 2023 as the companys state-of-the-art R&D and manufacturing facility. The post Moderna reports record for UK clinical trials in 2023/24 appeared first on European Pharmaceutical Review. This is an increase from 14 percent in 2022/23.
The Federal Trade Commission doesn’t get notified about every deal, which can lead to a slow consolidation of the market, said Lina Khan, chair of the FTC. She made these comments on Monday during the Oliver Wyman Health Innovation Summit 2023 held in Chicago.
With Novo Nordisk, Eli Lilly and AstraZeneca leading the way, Big Pharma's sales will grow 4% annually through 2030: analysts kdunleavy Mon, 10/02/2023 - 15:19
Ironwood Pharmaceuticals is paying $1 billion to acquire VectivBio, a biotech whose lead program could become a blockbuster treatment for a gastrointestinal disorder. Preliminary Phase 3 data are expected by the end of 2023.
Healthcare IT companies experienced a bounceback in venture capital deal activity during Q1 of 2023. Rebecca Springer, PitchBook ’s lead healthcare analyst, said she is optimistic that healthcare IT startups will be able to keep this momentum going, especially those focused on staffing and value-based care enablement.
David Finn, CHIME Association Executive Healthcare and Information Sector, lead of the cybersecurity pavilion initiatives at ViVE 2023, does not mince words. With ransomware attacks surging to an all time high this month, Finn said in an interview that security is no longer a defensive posture; we are engaged in a war.
The 2023 Benefit Consultant Sentiment INDEX offered robust insights and cast a spotlight on the evolving roles of employers as they navigate the changing healthcare landscape. Your insights offer leading, innovative points of view that can guide employers and peers. Do you advise self-insured employers?
Environmental Champions: Individuals or teams who are leading environmental or sustainability efforts within their organization or even outside of their day jobs. Read more Digital Crusaders ELITE 2023 Digital Crusader Don Abramo of Pharming Healthcare Inc. Transformational Leaders: People who change the way companies operate.
N-Nitrosamines By far the biggest issue bedevilling industry during 2023 was the continuing N-nitrosamine contamination saga, which was covered in the third issue of EPR 2023. During August 2023 the FDA also updated its guidance for NDSRIs 7 and it was closely aligned (but not identical) to EMA’s evolving guidance.
Data showed that TEAEs leading to treatment discontinuation were more frequent with quetiapine XR (11.0 Nasal spray could help prevent depression relapse The post ECNP 2023: new esketamine NS safety data for depression appeared first on European Pharmaceutical Review. There were 53.6 percent of quetiapine XR-treated patients.
From enabling patient choice during clinical trials to strengthening vital partnerships across the quality ecosystem, connected data will become the lifeblood that enables life sciences teams to collaborate efficiently and effectively in 2023. Data will unlock clinical and economic value in Europe’s challenging landscape.
A neurosteroid drug was one of two medicines recommended for approval at the Committee for Medicinal Products for Human Use (CHMP) ’s May 2023 meeting. This outcome was based on trial results, which compared the effectiveness and safety of Adakveo with placebo in patients who had previously had painful crises leading to a healthcare visit.
And in 2023, these investments will hopefully pay off. Leading companies will empower their teams to act quickly, compliantly, and with a unified view of the HCP.”. In 2023, omnichannel behaviours will directly influence incentive compensation models by correlating successful engagement data to successful sales outcomes.
For 20 of the leading biopharmaceutical companies, the second quarter (Q2) of 2023 has brought an aggregate market capitalisation growth of 2.3 trillion in the Q1 of 2023 to $3.56 trillion in Q2 2023. billion to revenue in Q2 2023. billion to revenue in Q2 2023. billion in Q2 2023. percent.
2023 is set to usher in a new era of genomics, and here are five areas where we should see significant advances. Just one mutation can lead to a complete change in protein formation. The post A new dawn of the genomic age: five areas set to be transformed in 2023 appeared first on.
According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028. Similarly, Almirall S.A.,
Today, we present our 2023 list , recognizing 6,849 individuals from more than 1,300 institutions across 67 countries and regions. By implementing an increasing number of qualitative criteria and markers this year, the number of preliminary candidates excluded from our final list increased from 500 in 2022 to more than 1,000 for 2023.
Janssen Pharmaceutical Companies of Johnson & Johnson’s data were featured at the European Society for Medical Oncology (ESMO) 2023 Congress. Martin Vogel, EMEA Therapeutic Area Lead Oncology, Janssen-Cilag GmbH highlighted that “standard-of-care for BCG-unresponsive HR-NMIBC is radical cystectomy”.
The Nobel Assembly has awarded Hungarian biochemist Katalin Karikó and US immunologist Drew Weissman the Nobel Prize in Physiology or Medicine 2023 for their breakthrough findings in RNA vaccine development. This leads to their activation and the release of inflammatory signalling molecules.
Would 2023 data show a second year of decline, indicating uncertain economic outlooks? It covers a commercial market with 27 member countries, a population of over 450 million people (larger than the United States), and an economy estimated to have a combined GDP of over $ 18 trillion USD in 2023 (larger than Mainland China).
In this blog, I share nine healthcare marketing trends you need to embrace in 2023 to remain competitive in today’s ever-changing healthcare marketplace. 9 Healthcare Marketing Trends 2023. Be sure to include staff recruitment in your 2023 marketing budget. Here’s to a successful 2023.
The drive to make the UK a ‘scientific powerhouse’ was central to the government’s announcement closing out 2022 , which appointed five industry experts to lead on the sectors most vital to UK’s future innovation. The post It’s time for more tech and biotech innovation in 2023 appeared first on. About the author. He holds a B.S.
MANUFACTURING Continuous direct compression: opening up faster access to oral dose medication Deborah McElhone, CPI’s Medicines Manufacturing Innovation Centre IN-DEPTH FOCUS: QA/QC MICROBIOLOGY Bioburden and sterility testing: how to conserve gene therapy product Kathy Zagaroli, Senior Director of Quality Control at Kiniksa Pharmaceuticals Tom Bujold, (..)
It’s wise advice from the “Sage of Omaha”; indeed, one highly respected financial newspaper began its 2023 predictions by conceding that it had been wrong on five major counts for 2022. Demand has also increased due to changes in prescribing protocols, leading to a higher underlying number of prescriptions for certain antibiotic medicines.
CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, announces that its President and CEO, Tracey Armstrong, was named to the Forbes 2023 “ 50 Over 50 ” list. The post Tracey Armstrong Named to Forbes 2023 “50 Over 50” List appeared first on Copyright Clearance Center.
September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. When production at the 17,200-ft 2 site begins, currently anticipated for the end of Q3 2023, the facility will further enhance bioproduction capabilities and contribute to the growth of the sector in France and Europe.
Sales Effectiveness Sales effectiveness refers to your sales team’s ability to convert prospects into leads — and eventually paying customers or clients — at each stage of your sales funnel. That is, how quickly you are able to convert users into leads/sales and while still generating the highest return on your investment.
This data was presented at the 2023 Fetal Medicine Foundation (FMF) World Congress in Spain. Dr Ludovic de Beaucoudrey, Therapeutic Area Lead for Immunology Janssen EMEA shared more about nipocalimab with EPR What is the mechanism of action for nipocalimab? There were 12 of the 13 pregnancies (92 percent) that resulted in a live birth.
HubSpot – This all-in-one platform helps sales and marketing teams attract more site visitors, convert more leads, and close more sales. Establish lead qualification criteria Almost 80% of leads never turn into sales. But you can improve your B2B conversion rates with a structured approach to analyzing your leads.
Cell and gene therapy industry in 2023 According to data from the GMP Manufacturing Survey, in the past year: “There is an increase in the number of manufacturing organisations and the number of licensed facilities has remained stable. The 2023 data found that the split for bioprocessing roles was 57 percent.
Jay Patel From our experience in patient research across many different treatments, we’ve defined several key insights on what may lead to nonadherence: Complex medication routines and patients feeling overwhelmed with their regimen. Inconvenient or challenging-to-adhere-to medications that have complex administration methods.
from 2023 to 2032, reaching $17.9bn across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) by the end of this forecast period, according to leading data and analytics company GlobalData’s recent report: Osteoporosis: Seven-Market Drug Forecast and Market Analysis.
In this issue: UK’s new Netflix-style funding model for antibiotics, the Swiss biotech ecosystem recuperates from financial instability of 2023, how patient advocacy can lead to more successful clinical trials, and more.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content